Literature DB >> 20027185

Regulation of cell signalling by uPAR.

Harvey W Smith1, Chris J Marshall.   

Abstract

Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways. Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling. Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20027185     DOI: 10.1038/nrm2821

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  177 in total

1.  Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.

Authors:  Denis Martin Schewe; Tobias Biller; Gabriele Maurer; Irfan A Asangani; Joerg H Leupold; Ernst R Lengyel; Stefan Post; Heike Allgayer
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

2.  Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.

Authors:  M Ploug; H Rahbek-Nielsen; P F Nielsen; P Roepstorff; K Dano
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.

Authors:  M R Gyetko; S Sud; J Sonstein; T Polak; A Sud; J L Curtis
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

4.  Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598.

Authors:  Y Koshelnick; M Ehart; P Hufnagl; P C Heinrich; B R Binder
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

5.  Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans.

Authors:  R Beschorner; H J Schluesener; T D Nguyen; V Magdolen; T Luther; I Pedal; R Mattern; R Meyermann; J M Schwab
Journal:  Neuropathol Appl Neurobiol       Date:  2000-12       Impact factor: 8.090

6.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

7.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.

Authors:  Nobuo Nagai; Kiyotaka Okada; Naoyuki Kawao; Chikako Ishida; Shigeru Ueshima; Desire Collen; Osamu Matsuo
Journal:  Neurosci Lett       Date:  2007-12-08       Impact factor: 3.046

9.  The absence of uPAR is associated with the progression of dermal fibrosis.

Authors:  Yosuke Kanno; Aki Kaneiwa; Misato Minamida; Miho Kanno; Kanji Tomogane; Koji Takeuchi; Kiyotaka Okada; Shigeru Ueshima; Osamu Matsuo; Hiroyuki Matsuno
Journal:  J Invest Dermatol       Date:  2008-06-12       Impact factor: 8.551

10.  Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene.

Authors:  E Lengyel; H Wang; E Stepp; J Juarez; Y Wang; W Doe; C M Pfarr; D Boyd
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

View more
  344 in total

1.  Ly6G ligation blocks recruitment of neutrophils via a β2-integrin-dependent mechanism.

Authors:  Jun-Xia Wang; Angela M Bair; Sandra L King; Ruslan Shnayder; Ya-Fang Huang; Chi-Chang Shieh; Roy J Soberman; Robert C Fuhlbrigge; Peter A Nigrovic
Journal:  Blood       Date:  2012-06-01       Impact factor: 22.113

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  Structure of collagen receptor integrin α(1)I domain carrying the activating mutation E317A.

Authors:  Matti Lahti; Eva Bligt; Henri Niskanen; Vimal Parkash; Anna-Maria Brandt; Johanna Jokinen; Pekka Patrikainen; Jarmo Käpylä; Jyrki Heino; Tiina A Salminen
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

4.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

5.  Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Authors:  Alexander Kapustin; Victoria Stepanova; Natalia Aniol; Douglas B Cines; Alexei Poliakov; Serge Yarovoi; Tatiana Lebedeva; Robin Wait; Grigory Ryzhakov; Yelena Parfyonova; Yaroslav Gursky; Hiromi Yanagisawa; Mikhail Minashkin; Robert Beabealashvilli; Alexander Vorotnikov; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2012-04-15       Impact factor: 3.857

6.  Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways.

Authors:  Hong-Beom Bae; Jaroslaw W Zmijewski; Jessy S Deshane; Degui Zhi; Lawrence C Thompson; Cynthia B Peterson; David D Chaplin; Edward Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

7.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain.

Authors:  Paola Merino; Ariel Diaz; Luis Guillermo Manrique; Lihong Cheng; Manuel Yepes
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

Review 9.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

Review 10.  Extrarenal determinants of kidney filter function.

Authors:  Eunsil Hahm; Vasil Peev; Jochen Reiser
Journal:  Cell Tissue Res       Date:  2017-05-30       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.